Evidence map›Paper›PMID 41008840›Full record

ArticleCancers2025

Characterisation of mAb104 Antibody-Drug Conjugates Targeting a Tumour-Selective HER2 Epitope.

Sagun Parakh, Nhi Huynh, Laura D Osellame, Diana D Cao, Angela Rigopoulos, Benjamin Gloria, Nancy Yanan Guo, Fiona E Scott, Zhanqi Liu, Hui K Gan and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sagun ParakhTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne 3084, Australia.ORCID 0000-0003-3891-2489
Nhi HuynhTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne 3084, Australia.
Laura D OsellameTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne 3084, Australia.
Diana D CaoTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne 3084, Australia.
Angela RigopoulosTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne 3084, Australia.ORCID 0009-0006-0811-7731
Benjamin GloriaTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne 3084, Australia.
Nancy Yanan GuoTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne 3084, Australia.
Fiona E ScottTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne 3084, Australia.ORCID 0009-0003-3190-6518
Zhanqi LiuTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne 3084, Australia.
Hui K GanTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne 3084, Australia.
Andrew M ScottTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne 3084, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe novel anti-HER2 antibody 104 (mAb104) targets a unique tumour-specific epitope, lacks normal tissue binding and can internalise into tumour cells, thus supporting its development into antibody drug conjugates (ADCs).

methodsWe now describe the binding properties and preclinical activity of mAb104-ADCs developed through the conjugation of mAb104 via linkers to the anti-microtubule drug maytansoinoid ematansine (DM1-SMCC; DM1), topoisomerase I inhibitor, exatecan derivative (MC-GGFG-DX8951; DX8951) or microtubule disruptor monomethyl auristatin E (MC-vc-PAB-MMAE; MMAE).

resultsMab104-ADCs demonstrate dose-dependent cytotoxicity in vitro. The safety of single-dose mAb104-DX8951 was demonstrated in vivo at doses up to 10 mg/kg. MAb104-ADCs also demonstrated potent and prolonged anti-tumour activity in a range of tumour types with variable HER2 expression. Mab104-DX8951 showed significant responses in trastuzumab-resistant HER2-positive breast cancer, low HER2-expressing cancers, as well as HER2-overexpressing cancers.

conclusionThese findings indicate the potential for tumour-specific targeting of HER2-expressing tumours with mAb104-ADCs.

Indexed as

antibody drug conjugatesepitopeHER2osimertinib-resistanttrastuzumab-resistant

Identifiers

PMID41008840
PMCPMC12468726

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.